LYB vs SPRO · P/E 21, rev $40.30B vs P/E 9.6, rev $48.0M
LyondellBasell Industries NV (LYB) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
LyondellBasell Industries NV (LYB) is a specialty chemicals company listed on US.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported LYB revenue for 2024-12-31 was $40.30B. Net income was $1.37B. Revenue was down 2.0% from 2023-12-31 to 2024-12-31. LYB currently screens at market cap $19.93B and trailing P/E 21.5.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
LYB currently screens at market cap $19.93B and trailing P/E 21.5. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the LYB and SPRO stock pages for the full models.
Not investment advice.